JLP-1207
DrugThe subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
NCT Number: NCT02494349
The purpose of this study is to investigate and compare the pharmacokinetic characteristics and safety/tolerability between JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg)and co-administration of Solifenacin and Tamsulosin between Solifenacin and Tamsulosin in healthy male volunteers.
Looking for future studies?
Notify Me19 year–45 year
Male
Interventional
Phase 1
A randomized, open-label, single dose, two-way crossover study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
Time frame: 192 hours
Time frame: 192 hours
Time frame: 192 hours
Time frame: 192 hours
Time frame: 192 hours
Time frame: 192 hours
Jeil Pharmaceutical Co., Ltd.
Industry
Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207 and Soifenacin/Tamsulosin in Healthy Male Volunteers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07723378
Benign Prostate Hypertrophy(BPH), Genital Diseases
Moscow, Russia
View Trial DetailsNCT06839768
Benign Prostate Hypertrophy(BPH), Genital Diseases
Moscow, Russia
View Trial DetailsNCT07276919
Acute Urinary Retention, LUTS(Lower Urinary Tract Symptoms)
Beijing, Outside U.S./Canada, China
View Trial DetailsNCT05401032
BPH, LUTS(Lower Urinary Tract Symptoms)
Braga, Portugal
View Trial Details